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Introduction 19 
Epilepsy is one of the most common neurological disorders and it puts a big burden on health care systems, 20 
requiring a long-term drug treatment [1]. 21 
In 1996, the World Health Organization (WHO) launched the methodology defining the daily dose (DDD), a 22 
widely used tool in drug utilization studies [2, 3]. Although DDD is an average maintenance dose in adults by 23 
definition [4] and a unit used in drug consumption, notwithstanding, contradictions with prescribed daily dose 24 
(PDD) can be observed [2, 5]. Based on prescription data, Hsieh and Huang reported lower or similar PDDs of 25 
the most commonly used AEDs in monotherapy compared to polytherapy in a nation-wide drug utilization study. 26 
Although significantly higher doses were confirmed between monotherapy and polytherapy groups among 27 
carbamazepine (CBZ), valproate (VPA) and gabapentin (GBP) users, in both groups the PDD/DDD ratios were 28 
lower than 1.00 [6]. Similar findings were published in a Czech study [7] and in a comparative study based on 29 
Swedish and Czech data [8]. Both studies used PDDs of patients’ data who had undergone therapeutic drug 30 
monitoring (TDM). 31 
Studies have confirmed that combination therapy is used in the minority of cases; notably, the proportion of 32 
combination therapy reported in four studies by Brodie et al. [9], Kořístková et al. [7, 8] and Rochat et al. [10] 33 
fell in the range of 15-38.2%. Accordingly, there is another contradiction between clinical practice and DDDs of 34 
AEDs assigned for combination therapy in the case of AEDs by WHO [4]. 35 
DDD is used not only as a simple number to compare different periods and/or regions, it is used, e.g., for the 36 
estimation of ever-users’ prevalence in the equation of population attributable risk (PAR) [11-13]. Further 37 
importance of the DDD has been published by Kwan et al. and Brodie et al. who concluded that effective seizure 38 
control could be achieved at 50% or 75% of DDD and could be applied to the definition of drug-resistant 39 
epilepsy [14, 15]. 40 
 41 
Aim of the study 42 
The aim of this study was, first, to determine PDDs of AEDs and to reveal PDD/DDD ratio among seizure free 43 
vs. not seizure free patients in everyday clinical practice. Second, to test the applicability of 75% cut-off of DDD 44 
to achieve seizure freedom. Furthermore, it was our intention to find out what factors might influence PDD. 45 
Ethics approval 46 
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All procedures performed in studies involving human participants were in accordance with the ethical standards 47 
of the institutional and/or national research committee and with the Helsinki declaration of 1964 and its later 48 
amendments or comparable ethical standards. For this type of study no formal consent is required. Ethical 49 
approval was obtained from the Regional and Institutional Research Ethics Committee (DEOEC RKEB/IKEB: 50 
2584A-2007). 51 
Methods 52 
A cross-sectional retrospective database was compiled from the outpatient files covering the period between 53 
November 1992 and December 2011 at the outpatient unit of the department of neurology, at the medical centre 54 
of a university [16]. 55 
This epilepsy outpatient unit provides care for patients from 16 years of age. As the university is a tertiary 56 
referral hospital of the Northern Great Plain and Northern Hungary, the majority (67%) of the patients are from 57 
Debrecen and the rest come from 3-4 counties of Hungary. 58 
All the patients in the study were coded with epilepsy diagnoses in accordance with the International 59 
Classification of Diseases by the WHO [17]. The data of 1282 patients who had taken AEDs were retrieved from 60 
the database and analysed on the basis of gender, age, age at seizure onset, seizure type (generalized and focal), 61 
seizure freedom status as an outcome of treatment, and PDD. PDD was calculated on the basis of the proposed 62 
dosage regimen of the last follow-up visit. For each patient, DDD% was computed as the percentage of PDD 63 
divided by DDD and mean DDD% was calculated in order to compare different groups. The 75% cut-off have 64 
been chosen based on Brodie et al.’s suggestion [15]. Current age and age at seizure onset were distinguished for 65 
further analysis. Patients aged 16-40, 41-65 and over 65 were included in the former group, and childhood (0-14-66 
year-old), adolescence (15-20-year-old) and adulthood (>21-year-old) were categories in the latter group of 67 
patients. According to the definition by the International League Against Epilepsy, in this study, seizure freedom 68 
was considered at least three times the interval of the longest previous interseizure duration (determined from 69 
seizures occurring within the past 12 months), or 12 months, whichever was longer [18]. 70 
The relationship of PDD to DDD was analysed in 894, 286 and 102 epileptic patients on monotherapy, bitherapy 71 
and polytherapy, respectively. The most commonly used AEDs and their role in the outcome of these groups 72 
were compared. The attending epileptologist chose the best treatment modality for each patient. The first 73 
treatment always was monotherapy; the second choice was either an alternative monotherapy or a combination 74 
of the first or second monotherapies together with a second AED, and so on [19-23]. 75 
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AED doses were prescribed according to the summary of product characteristics (SPC) to a mid-range dose, and 76 
were further increased up to the maximally tolerated dose in case seizures occurred repeatedly. When needed, 77 
TDM was performed and assessed to guide dosage changes and also to test patient compliance [24]. In case of 78 
seizure freedom, the dosage of AED was not increased further. An AED was changed due to lack of efficacy or 79 
poor tolerability. 80 
Since newer AEDs are widely available on the Hungarian market, they can be compared with the older ones. 81 
Statistical analysis was carried out using the SPSS for Windows 19.0 (SPSS Inc. Chicago, USA) and Microsoft 82 
Office Excel 2007. 83 
Two-sample T test, and F test were used to analyse the patients’ data. Categorical variables were assessed with 84 
Pearson χ2 test. 85 
A logistic regression model was created in order to analyse what factors characterised 75% DDD cut-off; the 86 
dependent variable was equal to or less than 75% of DDD and more than 75% of DDD. The independent 87 
variables included gender, age group, age at the onset of seizure, type of seizure, seizure freedom, other CNS 88 
related drugs and number of AEDs. 89 
Differences were considered significant if p<0.05. 90 
Results 91 
At the time of the analysis, of the 1282 patients (male: 608 [47.4%] and female: 674 [52.6%]), 894 (69.7%) were 92 
on monotherapy, 286 (22.3%) on bitherapy and 102 (8%) on polytherapy. The baseline characteristics of the 93 
patients has been assessed in Table 1. 94 
Comparing the number of prescribed old and new AEDs, a significant increase was observed in the proportion of 95 
newer AEDs between the mono- versus bitherapy (p<0.0001) and bi- versus polytherapy groups (p=0.0003; 96 
Table 2). 97 
Other drugs acting on the CNS were taken by 279 patients (22%). In the previous study published recently, we 98 
found the pooled group of other CNS-acting drugs had an effect on seizure freedom [16]. Twenty-two out of 279 99 
patients took other CNS-acting drugs belonging to ATC N05 and N06. Only bupropion, risperidon and sertraline 100 
were identified to have interacted with four AEDs (carbamazepine, lamotrigine, phenytoin and valproate). As 101 
only 12 patients might have had these potential interactions we disregarded analysis in this group due to the low 102 
case number. 103 
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In the study population, the patients did not take more than the maximum recommended doses for AEDs in the 104 
SPC. 105 
DDD values, mean PDDs of AEDs and distribution of prescribed AEDs in each group are summarized in Table 106 
2. The mean number of AEDs per patient was 1.4. Using bitherapy the old-old, old-new and new-new type 107 
AED-combinations were prescribed for 118 (41%), 133 (47%) and 35 (12%) patients, respectively. 108 
No significant gender differences were confirmed between seizure free and not seizure free groups. The mean 109 
antiepileptic dose was higher among males (p<0.001) only in the group on monotherapy. 110 
The mean DDD% of all prescribed AEDs increased steadily from monotherapy, through bitherapy towards 111 
polytherapy (58.54%±24.04, 74.38%±42.89, 93.68%±54.82, respectively). 112 
The effects of the most commonly used AEDs on seizure freedom status in mono-, bi-, and polytherapy are 113 
demonstrated in Figure 1. 114 
CBZ and oxcarbazepine (OXC) showed similar patterns but CBZ was prescribed in less than 75% of DDD, 115 
while OXC was prescribed in all scenarios in more than 75% of DDD (Figure 1 C and E). 116 
In the case of VPA, mono- and bitherapy PDDs remained below 75% of DDD but in the group on polytherapy a 117 
higher dose did not increase the likelihood of seizure freedom (Figure 1 D). 118 
Monotherapy 119 
Mean PDDs mostly fell in the range between 50-75% of DDDs (Table 2). 120 
With the exception of OXC and GBP, the mean DDD% was higher in the group of not seizure free patients 121 
(Table 3). Except for OXC, the vast majority of seizure free patients had taken AED doses in the range of ≤75% 122 
of DDDs in monotherapy. Not seizure free patients were treated with higher doses of LTG, and significant 123 
differences in means could be seen between seizure free and not seizure free cohorts (p=0.02; Table 3 and Figure 124 
1 B). 125 
The mean DDD percentage was equal to or less than 75% in most AEDs used in monotherapy in the group of 126 
seizure free patients. A significant difference was revealed only among LTG users (p=0.032) in favour of ≤75% 127 
of DDD and seizure free patient’s group. The mean DDD% exceeded 75% in four cases as follows: clobazam 128 
(CLB), OXC, topiramate (TPM) and lacosamide (LCM), 100%, 86.82%, 133.3% and 133.3%, respectively. No 129 
preferable AED was confirmed based on general effectiveness (p=0.65) in relation to desired seizure free status 130 
(Table 4). 131 
Low case numbers (<10 patients or <1%) characterised CLB, clonazepam (CZP), primidone (PRM), sultiame 132 
(STM), LCM and TPM prescriptions used in monotherapy. Eighty percent of these patients were seizure free. 133 
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Only 30% of the patients took 100% or more of DDD (CLB, LCM and TPM) and all had seizure freedom (Table 134 
3). The majority of seizure free patients were females (75%; p<0.0001). 135 
Bitherapy 136 
The mean PDDs of CBZ, VPA, PRM, CLZ, GBP and VGB were within 50-75% of DDD (Table 2). 137 
Significantly higher mean DDD% was observed between seizure free and not seizure free cohorts taking 138 
levetiracetam (LEV; p=0.023; Table 3 and Figure 1). Slightly higher mean DDD% was revealed among seizure 139 
free patients on CLB and PRM (Table 3). 140 
The majority of patients belonged to the group of equal to or less than 75% of DDD (except CLB, OXC, 141 
phenytoin [PHT], Table 3). 142 
Despite low case numbers, female dominance was found in the bitherapy group; only three out of the sixteen 143 
patients were males. Less than one third of the patients (all females) were seizure free. More than two thirds of 144 
the patients had taken 100% or more than the DDD. 145 
Polytherapy 146 
Only PDDs of CBZ, PHT, PRM and CLZ remained under 75% of DDD (Table 2). 147 
The mean DDD% was higher among not seizure free patients but no significance was confirmed (except CBZ 148 
p=0.032 and GBP p=0.045; not seizure free patients taking LEV and TPM had lower values but the differences 149 
were not significant; Table 3). 150 
In polytherapy, the use of more than 75% of DDDs was recorded in the seizure free and not seizure free groups 151 
receiving LEV, LTG, OXC and TPM (Table 4). The mean DDD% was higher among TPM, PRM and LEV users 152 
in the seizure free group. 153 
Among the older types of AEDs, both CBZ and VPA had to be given in a significantly higher mean dose in 154 
bitherapy than in monotherapy in the seizure free group and in polytherapy in the not seizure free group. Among 155 
the newer types, only LEV and LTG had a significantly higher DDD% series pattern between mono-, bi-, and 156 
polytherapy in both groups (except LEV in polytherapy in the not seizure free) group. 157 
The mean DDD% of CBZ and GBP in polytherapy was significantly higher in not seizure free patients than in 158 
the seizure free group (p=0.032 and 0.045, respectively; Table 3 and Figure 1 C). 159 
There was no identical combination in polytherapy with five AEDs and only two out of seventeen patients 160 
shared the same four-drug combination. Among the 79 patients taking three AEDs, 31 patients had an own triplet 161 
for controlling epilepsy. 162 
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Only one fifth of the patients were seizure free (two thirds of them were females) in the low case number 163 
category. Sixty percent of the patients took less than 100% of DDD. Although patients in the polytherapy group 164 
took three times the DDD of phenobarbital (PB) they were not seizure free. 165 
Logistic regression analysis 166 
In this model, gender, age group, type of seizure, seizure freedom and number of AEDs all had a significant 167 
impact (all p<0.05). No link was revealed with age at the onset of seizure or other drugs acting on the CNS. 168 
In the logistic regression model, gender served as a significant predictor (p=0.001; Exp(B) [exponentiation of the 169 
B coefficient]= 1.456, 95% CI [Confidence Interval]: 1.169-1.813) if it was equal to or less than 75% of DDD 170 
among men. 171 
Current age showed significant difference in the model of ≥75% of DDD in the over 65-year-old group 172 
(p=0.022; Exp(B)= 1.449, 95% CI: 1.055-1.989). 173 
The odds were higher for focal seizures in more than 75% of DDD group (p=0.002; Exp(B)= 0707, 95% CI: 174 
0.568-0.881) and equal to or less than 75% of DDD in generalized seizure. 175 
There was no higher chance for seizure freedom if more than 75% of DDD was prescribed (p= 0.027, Exp(B)= 176 
0.773, 95% CI: 0.616-0.971). 177 
As a result of increasing the number of AEDs, a higher portion of more than 75% of DDD could be achieved in 178 
the logistic regression model. 179 
Discussion 180 
The treatment of epileptic patients is complex. Of course, there are conditions (drug interactions, individual 181 
differences in drug metabolism, age, comorbidities, etc.) that emphasise the importance of individual treatment 182 
in finding the proper dosage of AED. However, evidence including DDD, clinical trials or TDM is important 183 
when choosing the best AED treatment for the patient. 184 
The study by Hsieh and Huang retrieved prescription records for all patients, prescribed AEDs and calculated 185 
PDD/DDD ratio [6], but this was not related with the outcome. Meanwhile Kořístková et al. [7, 8] and Lammers 186 
et al. [25] considered TDM data besides the PDD/DDD ratio. Serum level monitoring of AEDs is not widely 187 
available for every AED, and serum level does not always reflect clinical status. 188 
In our study, a new, clinically important, well-defined and feasible approach was tried in order to determine the 189 
correlation between PDD and PDD/DDD ratios based on seizure freedom as an outcome of AED treatment. One 190 
of our goals was to see whether PDD/DDD could play a role in seizure freedom as an outcome measure in 191 
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epilepsy; no significant unfavourable impact of the lower ratio of PDD/DDD on the outcome of achieving 192 
seizure freedom could be confirmed. 193 
Further decrease in the number of AEDs was confirmed (1.4) when we compared the data of our recent study 194 
with those by Guelen et al. [26], Lammers et al. [25] reporting 3.2 and 1.7 AEDs per patient, respectively. 195 
The majority of patients (894 [69.7%]) took only one AED and just 102 (8%) patients took more than two AEDs. 196 
In a Danish study including 3756 patients, almost the same distribution was published in 2001 [10]. Kořístková 197 
et al (2006) described a similar monotherapy cohort among patients involved in therapeutic drug monitoring in a 198 
Czech and Swedish University Hospital [8]. Hsieh and Huang reported only 51.9% monotherapy rate in a 199 
randomly sampled population of 167 377 patients, which was less than the catchment area of our study [6]. 200 
Most of the patients (764 [85.4%]) in the monotherapy group were treated with three AEDs (CBZ, VPA and 201 
LTG). Newer AEDs were prescribed for more than a quarter of the patients which is higher than in a study 202 
conducted in Taiwan, where the prescription rate of newer AEDs was under 10% [6]. However, according to our 203 
data and similar to publications by others [7-10], AEDs – including more newer type ones – are prescribed in 204 
monotherapy for more and more patients, but while DDDs of AEDs refer to combination therapy. Therefore, 205 
references of monotherapy DDD values are needed for appropriate calculation. The more precisely DDD is 206 
quantified the more accurate calculation of other derived values (e.g. DDD/1000 inhabitants/day, prevalence of 207 
drug use, population attributable risk) it would provide, which could also play an important role in decision-208 
making in health care. 209 
A significant increase was observed in the proportion of newer AEDs in our database. Probably these data were 210 
obtained with due consideration to the different modes of action of AEDs and their favourable ADRs in 211 
bitherapy and polytherapy. 212 
In our outpatient setting, the mean PDDs of AEDs were inconsistent with the DDD. Previous investigations were 213 
of the same opinion [8, 10, 27]. 214 
The mean DDD% was equal to or less than 75% for the most commonly prescribed AEDs used in monotherapy 215 
in the seizure free group. In contrast with our findings, Hsieh and Huang (2009) did not reveal more than 100% 216 
of DDD [6]. One of the explanations might be that older AEDs were prescribed more circumspectly due to their 217 
well-known ADRs. At the same time, the ADR profiles of new AEDs were considered more beneficial. In case 218 
of two newer types of AEDs (LTG and LEV) a significant rise in doses between mono-, bi-, and polytherapy was 219 
detected, by other AEDs a wide variety of mean DDD% supposes individual treatment regimen. Still CBZ and 220 
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VPA are widely prescribed in the clinical practice due to reliable effectiveness and their broad-spectrum. These 221 
drugs can be used in low and moderate doses, too. 222 
Our findings suggested that doses equal to or less than 75% of DDD in monotherapy were effective in seizure 223 
control and the same quantities were confirmed in bi-, and polytherapy. However, a higher DDD% did not 224 
guarantee seizure freedom which emphasises the importance of individual therapy. 225 
It must be remarked that despite the low case numbers of some AEDs (e.g. CLB, CZP, PRM, STM, LCM and 226 
TPM) which were statistically unfit for analysis the majority of the patients on these agents were seizure free. 227 
These findings highlighted the importance of carefully choosing drugs carefully, i.e. tailored to the individual 228 
e.g. in the treatment of special epileptic syndromes. 229 
Prescribing newer AEDs in bitherapy drug combinations has become an established practice now. This research 230 
has revealed the spread of newer type AEDs in epilepsy treatment but they are used not only in combinations, 231 
but also in monotherapy among patients on AEDs. The findings of this study suggest that individual therapy in 232 
epilepsy must be emphasised but 75% of DDD may also be used as a measure in case of seizure freedom. Just 233 
under 60% of patients took at least one newer AED in this study, in contrast with the findings by Hsieh and 234 
Huang (2009) who reported 13.2% in their polytherapy group (they used this term for patients taking two or 235 
more AEDs) [6]. New-new combinations were given to 38 (12.2%) patients on bitherapy and 133 (46.5%) 236 
patients took old-new combinations. In choosing the second and third AEDs it may have played an important 237 
role whether or not the specific AED had an enzyme-inducing or enzyme-inhibiting effect on the liver’s enzyme 238 
system. 239 
Dominance of equal to or less than 75% of DDDs could be found in the bitherapy group. A statistically 240 
significant, higher DDD% was confirmed between seizure free and not seizure free groups only when LEV was 241 
administered. 242 
With logistic regression analysis, gender, age, type of epilepsy and the number of AEDs were found to have had 243 
a significant impact on the value of 75% DDD. These were the factors what influenced PDD. These might be 244 
limiting factors when making conclusions in studies using DDD. 245 
The present study confirmed that the DDD of prescribed AEDs was equal to or less than 75% of DDD instead of 246 
being over 75% among elderly patients. It was in accordance with well-known pharmacokinetic and 247 
pharmacodynamic changes in older ages and due to comorbidities and co-medications. 248 
It must be mentioned that, similarly to Kwan et al. [14] and Brodie et al. [15], our findings also emphasise 249 
individual therapy and the importance of 75% of DDD. 250 
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This study has several limitations as it is an observational study and not a randomized, controlled trial, that is 251 
why selection bias could have affected the results. Nevertheless, the advantage is detailed information on all 252 
subjects can be regarded as an important advance in this field. Further strength of this study may be the real-life 253 
data sets leading to a better understanding of real-life clinical settings and the outcome of routine epilepsy 254 
treatment. In this study, seizure freedom was chosen as a measure of outcome. Nevertheless, in everyday clinical 255 
practice, reduction in seizure frequency by 50% is an acceptable or good outcome in certain cases despite the 256 
fact that the patients are not seizure free. 257 
Conclusion 258 
In conclusion, no significant unfavourable impact of the lower ratio of PDD/DDD on the outcome of achieving 259 
seizure freedom has been confirmed. The findings of this study suggest that 75% of DDD may be used as a 260 
measure of seizure freedom, but individual therapy in epilepsy must be emphasised. Gender, age, type of seizure, 261 
seizure freedom and the number of AEDs have a significant impact on the 75% cut off value of DDD. 262 
References for monotherapy DDD values are needed, in order to help with decision-making in health care using 263 
appropriate calculations. 264 
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